ストックスクリーナーアプリを入手
7.53
6.06%
0.43
アフターアワーズ：
7.53
前日終値:
$7.10
開ける：
$7.2
24時間の取引高:
360.49K
Relative Volume:
1.63
時価総額：
$491.91M
収益：
-
当期純損益:
$-38.61M
株価収益率:
-7.593
EPS:
-0.9917
ネットキャッシュフロー:
$-29.20M
1週間 パフォーマンス:
+19.71%
1か月 パフォーマンス:
+5.17%
6か月 パフォーマンス:
+20.87%
1年 パフォーマンス:
+94.57%
1日の値動き範囲:
$7.17
$7.55
1週間の範囲:
$6.2689
$7.55
52週間の値動き範囲:
$3.8173
$9.32
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Compare EPRX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
7.53 | 463.82M | 0 | -38.61M | -29.20M | -0.9917 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-23 | 開始されました | William Blair | Outperform |
| 2025-07-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-06-26 | 開始されました | H.C. Wainwright | Buy |
| 2025-06-16 | 開始されました | Canaccord Genuity | Speculative Buy |
| 2025-02-21 | 開始されました | Craig Hallum | Buy |
| 2024-11-14 | 開始されました | Rodman & Renshaw | Buy |
すべてを表示
Eupraxia Pharmaceuticals Inc (EPRX) 最新ニュース
Eupraxia Pharmaceuticals (EPRX) Q1 2026 Earnings: Clinical Progress Overshadows Slight EPS MissLong-Term Guidance - Newser
Stifel Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Eupraxia Pharmaceuticals (EPRX) Q1 2026 Miss: What Went WrongCommunity Exit Signals - Newser
Stifel Initiates Eupraxia Pharmaceuticals at Buy With CA$34.37 Price Target - Moomoo
This SailPoint Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Benzinga
Certain Non-Voting Class B Shares of Eupraxia Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. - marketscreener.com
Certain Stock Options of Eupraxia Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. - marketscreener.com
Certain Common Shares of Eupraxia Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. - marketscreener.com
Stifel initiates Eupraxia Pharmaceuticals stock with buy rating - Investing.com
Stifel initiates Eupraxia Pharmaceuticals stock with buy rating By Investing.com - Investing.com Canada
LifeSci Capital Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Maintains Target Price $16 - Moomoo
H.C. Wainwright Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
William Blair Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating - Moomoo
EPRX SEC FilingsEupraxia Pharmac 10-K, 10-Q, 8-K Forms - Stock Titan
Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results - Sahm
Manchester entities, Besser & Frank disclose EPRX holdings (EPRX) - Stock Titan
Eupraxia Pharmaceuticals Reports Stronger Balance Sheet but Wider Q1 2026 Loss in Form 6-K Filing - TipRanks
Eupraxia Pharmaceuticals: Well-capitalized Into 2H28 >EPRX.T - Moomoo
Eupraxia Pharmaceuticals reports first quarter 2026 financial results - marketscreener.com
Eupraxia Pharmaceuticals Q1 Loss Narrows - Moomoo
Eupraxia (NASDAQ: EPRX) funds EP-104GI trial despite higher quarterly loss - Stock Titan
Eupraxia Pharmaceuticals Says "Well-capitalized into Second Half 2028, Beyond Key Catalysts" With Over US$140M Cash - marketscreener.com
Eupraxia Pharmaceuticals Cites "Robust Response" In Highest Dose Cohort After 36 Weeks Following a Single Treatment of EP-104GI - marketscreener.com
Eupraxia Pharmaceuticals Incurred a Q1 Net Loss of US$12.7M - marketscreener.com
EPRX: Eupraxia Pharmaceuticals Inc.Interactive Chart - Zacks Investment Research
Aisling Capital Management LP's Eupraxia Pharmaceuticals Inc(EPRX) Holding History - GuruFocus
TradingKey - TradingKey
Number of shareholders of Eupraxia Pharmaceuticals, Inc. – FWB:X43 - TradingView
Eupraxia wins new (US) $15.50 target at Leede Financial - Cantech Letter
Eupraxia reports EoE trial data on inflammation and fibrosis By Investing.com - Investing.com India
Eupraxia Pharmaceuticals Inc. - Menafn.com
Stocks in play: Eupraxia Pharmaceuticals Inc. - Barchart.com
Eupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week - Investing News Network
Eupraxia reports EoE trial data on inflammation and fibrosis - Investing.com UK
Eupraxia Pharmaceuticals Posts Strong Histologic Gains in Mid-Stage EoE Trial for EP-104GI - TipRanks
Eupraxia Pharmaceuticals’ First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week - The Manila Times
In Eupraxia’s top-dose EoE cohort, tissue scores improved >90% - Stock Titan
Eupraxia (EPRX) shows >90% EoE tissue score gains at top RESOLVE dose - Stock Titan
Eupraxia reports endoscopy score data from EoE trial By Investing.com - Investing.com Australia
Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week - Investing News Network
Eupraxia reports endoscopy score data from EoE trial - Investing.com UK
Eupraxia Pharmaceuticals Highlights Strong EP-104GI EoE Data From RESOLVE Trial at DDW - TipRanks
Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW) - The Manila Times
Why 20 shots matter: Eupraxia links fuller dosing to lower EoE scope scores - Stock Titan
Why Eupraxia Pharmaceuticals (EPRX) guidance matters more than actual results | Q4 2025: Below ExpectationsHold Rating - newser.com
Eupraxia Pharmaceuticals Price Target Maintained With a $11.00/Share by HC Wainwright & Co. - Moomoo
Eupraxia Pharmaceuticals' (EPRX) Buy Rating Reiterated at HC Wainwright - MarketBeat
Eupraxia Pharmaceuticals: Tambiah to Succeed Mark Kowalski - Moomoo
Eupraxia appoints Dr. Jeymi Tambiah as chief medical officer By Investing.com - Investing.com India
Eupraxia Pharmaceuticals Names New Chief Medical Officer to Steer Late-Stage Pipeline - TipRanks
Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer - Investing News Network
Eupraxia Pharmaceuticals Inc (EPRX) 財務データ
収益
当期純利益
現金流量
EPS
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):